Introduction {#Sec1}
============

*Achromobacter* spp. is a rarely nosocomial and community pathogen, being *Achromobacter xylosoxidans* the most frequent species among *Achromobacter* spp. isolates \[[@CR6], [@CR8], [@CR18]\]. Many reports of *A. xylosoxidans* infections are documented in immunocompromised and cystic fibrosis (CF) patients, where its pathogenic role has not yet been properly clarified \[[@CR7], [@CR8]\]. In Argentina, the relative frequency of *A. xylosoxidans* among the uncommon non-glucose-fermenting gram-negative bacilli infections has been increasing reaching 66 % of total non-glucose-fermenting gram-negative bacilli infection isolates \[[@CR18]\].

Although clinical *A. xylosoxidans* isolates usually show multiple drug resistance, the relative low attention paid to this pathogen resulted in poor understanding of their resistance mechanisms. Little is known about molecular mechanisms and transferable elements contributing to the acquisition and dissemination of antibiotic resistance determinants in *A. xylosoxidans* clinical isolates.

The aim of this study was to explore the occurrence of mobile elements related to antibiotic-resistance determinants among a collection of 24 non-epidemiological-related clinical isolates of *A. xylosoxidans* recovered in Argentina from six centers.

Materials and Methods {#Sec2}
=====================

Bacterial Strains {#Sec3}
-----------------

Twenty-four non-epidemiological-related clinical isolates of *A. xylosoxidans* recovered in Argentina from six centers were used (Table [1](#Tab1){ref-type="table"}). All isolates were identified using standard biochemical tests and API 20NE (Biomeriux), and the species level was confirmed by sequencing the 16S rRNA gene \[[@CR19]\]. Clonal relationships analysis, using the macrorestriction technique, showed the presence of 15 different clones among the isolates included in the study (data not shown). The antibiotic susceptibility was performed by agar dilution method following the general recommendations of the Clinical and Laboratory Standards Institute (CLSI) \[[@CR4]\].Table 1Characteristic and obtained results of the 24 *A. xylosoxidans* isolates used in the studyIsolate^a^HospitalYearSource^b^IncPIS26IS440*intI1*vr^c^*intI2*Ax79Center 22004NP+−++*dfrA1*-*aadA1*+Ax169Center 32004NP+−++*dfrA1*-*aadA1*+Ax126Center 12001NP++−+*dfrA1*-*aadA1*+Ax144Center 12001NP+−+−NA−Ax69Center 22002CF−−+−NA−Ax72Center 22007CF+−−+*aac(6′)*-*Ib*−Ax77Center 22007CF−−+−NA−Ax210Center 32007CF−−−−NA−Ax81Center 22008CF−−−−NA−Ax82Center 22008CF−−−−NA−Ax90Center 22008CF−−−−NA−Ax91Center 22008CF−−−−NA−Ax92Center 22008CF−−−−NA−Ax93Center 22008CF−+−−NA−Ax97Center 22007CF−−−−NA−Ax336Center 22010CF−−+−NA−Ax11Center 22004NP−−−+*aac(6′)*-*Ib*−Ax22Center 11995NP−−−−NA−Ax44Center 12006NP+−−+*dfrA16*−Ax56Center 12003NP+−−+*aac(6′)*-*Ib*−Ax68Center 62010NP+−−−NA−Ax114Center 12002NP+−−+*dfrA1*-*aadA1*−Ax247Center 12006NP−−+−NA−Ax304Center 41996NP−−−+*bla*~OXA-2~−Ax2700Center 52006NP+−−−NA−*NA* not applicable^a^Isolates of the study: Ax for *Achromobacter xylosoxidans*^b^NP for nosocomial patient's samples and CF for cystic fibrosis patient's samples^c^vr: class 1 integron variable region

DNA Techniques {#Sec4}
--------------

Total DNAs were prepared and used as template for PCR reactions. PCR reactions were carried out using the GoTaq enzyme according to manufacturer's instructions (Promega, Madison, WI), and the products were detected by agarose gel electrophoresis. To reveal the presence of transferable determinants associated to horizontal gene transfer, specific primers for plasmids (IncP, IncW, IncA/C, IncN, IncFII, *repAci1*), transposons (Tn1331, Tn3, Tn7), insertion sequences (IS) (IS26, IS440), and the *bla*~ampC~, *intI1*, and *intI2* genes were used (Table [2](#Tab2){ref-type="table"}). The selection of the mobile elements was based on its association with antibiotic-resistance determinants and also its distribution in our hospitals \[[@CR12], [@CR13], [@CR16]\].Table 2Oligonucleotides used in the studyTargetOligonucleotideSequence 5′--3′References*IncW*TrwAB1AGCGTATGAAGCCCGTGAAGGG\[[@CR3]\]TrwAB2AAAGATAAGCGGCAGGACAATAACG\[[@CR3]\]*IncP*TrfA2 1CGAAATTCATATGGGAGAAGTA\[[@CR3]\]TrfA2 2CGTTTGCAATGCACCAGGTC\[[@CR3]\]*IncN*KikA1ACTTACCTTTATCAACATTCTGGCG\[[@CR3]\]KikA2CGACTGGTTACTTCCACCTTCGC\[[@CR3]\]*IncF*REPAGGAGCGATTTGCATTCCG\[[@CR3]\]REPCAAATGAGCCTGTTTGAG\[[@CR3]\]*IncA/C*CA1ATGTCGCAGACAGAAAATGC\[[@CR3]\]OR1CCTTGCAGTTTAATGTGAATAA\[[@CR3]\]IS26IS26FGCTGGCTGAACGCGGAG\[[@CR9]\]IS26RATACCTTTGATGGTGGC\[[@CR9]\]IS440IS440FCTCACTGTTCGCGACT\[[@CR9]\]IS440RGGCATGCGCAGTGAGCGG\[[@CR9]\]Tn1331Tn1331NFGAATTGCCTCGTGATACGCCTATTT\[[@CR15]\]Tn1331NRGCGGCCGCGATAGTTTGGCTGTGAGC AATT\[[@CR15]\]Tn3Tn3FAAGTTCATCGGGTTCGC\[[@CR9]\]201LACTACGATACGGGAGGGCT\[[@CR9]\]*tnsA*TnsAFCTCCATATTCACTACTTGGCT\[[@CR5], [@CR14]\]TnsARGCTAACAGTACAAGAAGTTCC\[[@CR5], [@CR14]\]*tnsB*TnsBFCATGTGGTCCAAGAACATAAG\[[@CR5], [@CR14]\]TnsBRGAGCAAGCATTTACAAAAGC\[[@CR5], [@CR14]\]*tnsC*TnsCFGTTTATCGTGATACGGGGG\[[@CR5], [@CR14]\]TnsCRGCTATCCCAGTCGCTGGG\[[@CR5], [@CR14]\]*tnsD*TnsDFGGGATTGTTAGTCCTAAGC\[[@CR5], [@CR14]\]TnsDRCCGTCTAATTTGATAATCTTC\[[@CR5], [@CR14]\]*tnsE*TnsEFTTGCTCTCTAACCACTCT\[[@CR5], [@CR14]\]TnsERTCGATTTGCTGCTTTTGATG\[[@CR5], [@CR14]\]*aac(6′)*-*Ib*aac(6)'ibFTGTGACGGAATCGTTGC\[[@CR13]\]aac(6)'IbRCAGTGACGGTTATTCCGC\[[@CR13]\]*intI1*Inti1FCGAGGCATAGACTGTAC\[[@CR12]\]Inti1RTTCGAATGTCGTAACCGC\[[@CR12]\]*intI2*Inti2FGCAAATGAAGTGCAACGC\[[@CR12]\]Inti2RACACGCTTGCTAACGATG\[[@CR12]\]5*′CS*SulproGCCTGACGATGCGTGGA\[[@CR12]\]3*′CS*3′CSAAGCAGACTTGACCTGATAG \[[@CR12]\]*sat*SatFTGAGCAGGTGGCGGAAAC\[[@CR12]\]SatRTCATCCTGTGCTCCCGAG\[[@CR12]\]*aadA1*aadA1rTCATTGCGCTGCCATTC\[[@CR12]\]aadA1TCGATGACGCCAACTAC\[[@CR12]\]*dfrA1*Dhfr1rCCTGAAATCCCCAGCAA\[[@CR12]\]dhfrA1AGCTGTTCACCTTTGGC\[[@CR12]\]*bla*~*OXA*-2~Oxa2FGAAGAAACGCTACTCGC\[[@CR12]\]Oxa2RTACCCACCAACCCATAC\[[@CR12]\]*dfrA16*Dhfr16FCAAAGGCGAGCAACTTCThis studyDhfr16RCACCCTCATCATTCGTAThis study

DNA Sequencing {#Sec5}
--------------

PCR products were sequenced after purifying the DNA by using the Wizard SV Gel and PCR clean-up System kit according to the manufacturer's directions (Promega, USA). Sequencing was performed on both DNA strands, using an ABIPrism 3100 BioAnalyzer equipment. The nucleotide sequences were analyzed using the Blast V2.0 software (<http://www.ncbi.nlm.nih.gov/BLAST/>).

Results and Discussion {#Sec6}
======================

The 24 *A. xylosoxidans* isolates studied exhibited the typical multiresistance profile previously described for this species, being the third and fourth-generation cephalosporins, fluoroquinolones, and aminoglycosides not active against *Achromobacter* spp. \[[@CR18]\]. All isolates were susceptible to tazobactam, imipenem, and meropenem (Table S1 in Supplementary material).

Among the PCR reactions performed for the selected transferable elements, positive results were obtained in ten isolates (42 %) for the IncP plasmids, a wide host range and self-transmissible plasmid important in the dissemination of resistant genes around the world \[[@CR11]\] (Table [1](#Tab1){ref-type="table"}). Negative results were obtained for the other Inc groups searched (IncW, IncA/C, IncN, IncFII). Sequence analysis of the amplification products showed 99 % of identity in 200-bp length with the replication gene *trfA* (AN GU186864). The GC% of the *trfA* replication gene of IncP plasmid is 60.5 %, which is very similar to the GC% (67 %) of *A. xylosoxidans*. We also noticed in this study that most isolates containing IncP plasmids corresponded to nosocomial isolates (*n* = 9). In only one CF patient isolate (Ax72), an IncP plasmid was identified.

Regarding IS and transposons, positive results were obtained for IS26 (*n* = 2) and IS440 (*n* = 7) (Table [1](#Tab1){ref-type="table"}), two ISs frequently associated to antimicrobial resistance genes and to classes 1 and 2 integrons \[[@CR1], [@CR2], [@CR10]\], obtaining negative results for the transposons Tn1331, Tn3, and Tn7.

In addition, a high dispersion of class 1 integrons was found (42 %). Most of the positive isolates corresponded to nosocomial patient samples (*n* = 9), being only one positive isolate from a CF patient sample (Ax72). To characterize the vr of class 1 integrons, PCR cartography was carried out as previously described \[[@CR12]\]. Four vr were identified, being all the arrays different to the previous arrays reported in this species (Table [1](#Tab1){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). Among the gene cassettes identified in the class 1 integron context, aminoglycosides-resistance genes *aac(6′)*-*Ib* and *aadA1*, the trimethoprim-resistance genes *dfrA1* and *dfrA16*, and the β-lactamase *bla*~OXA-2~ were found. The obtained MICs in the positive integron isolates to several antibiotics are exposed in Table [3](#Tab3){ref-type="table"}. No clear contribution of gene cassettes could be established in the studied isolates. Only in the strain Ax44, harboring the gene cassette *dfrA16*, a contribution to the MIC to TMS (256 μg/ml) could be suggested, as it corresponded to the highest value among isolates under scrutiny (Table S1 in Supplementary material).Fig. 1Schematic representation of arrays of class 1 integrons found among the *A. xylosoxidans* (*n* = 24) isolates. *Thin black vertical closed bar* The *attI1* site, *thin gray vertical closed bar* the *attC* sites of the gene cassettes. *Arrows* The primers used to identify the class 1 integron vr. Figure is not in scaleTable 3Minimal inhibitory concentration (μg/ml) of integron positive strainsIsolateCAZFEPPIPIPMMEMAMKGENTMPCIPvr^a^Ax798320.2510.1251281280.258*dfrA1*-*aadA1*Ax169321280.250.50.5128128116*dfrA1*-*aadA1*Ax1264320.510.251281280.12516*dfrA1*-*aadA1*Ax724320.2510.2525625646*aac(6′)*-*Ib*Ax1132128840.241281286464*aac(6′)*-*Ib*Ax4416320.510.51281282564*dfrA16*Ax56832820.0664320.1252*aac(6′)*-*Ib*Ax11416320.12510.1251281280.12516*dfrA1*-*aadA1*Ax30432128840.125128128324*bla*~OXA-2~*CAZ* ceftazidime, *FEP* cefepime, *PIP* piperacillin, *IPM* imipenem, *MEM* meropenem, *AMK* amikacin, *GEN* gentamicin, *TMP* trimethoprim-sulfamethoxazole, *CIP* ciprofloxacin^a^vr: class 1 integron variable region found in the Ax isolates

Furthermore, three nosocomial isolates apart from harboring class 1 integrons also have class 2 integrons (Ax79, Ax126, and Ax169) (Table [1](#Tab1){ref-type="table"}). To identify the gene cassette content found in the variable region of class 2 integrons, PCR cartography was performed using different combinations of primers \[[@CR5], [@CR14], [@CR16]\]. Only positive amplifications were obtained for the Ax126 showing the presence of the array *intI2*-*sat2*-*aadA1*. The occurrence of the Tn7 transposition gene was also searched, showing that the *tnsE* gene was present in all isolates, being the *tnsB* also present in the Ax126 isolate. The rest of the genes gave negative results. To the best of our knowledge, this is the first description of class 2 integrons in *Achromobacter* spp. \[[@CR16]\]. No association of integrons with IS26 and IS440 was found in this study.

In relation with the *bla*~ampC~ gene previously described in this species \[[@CR17]\], it was found in all isolates, confirming its ubiquitous nature.

The exposed results showed that almost all isolates (17/24) included in this study have the capability of carrying ISs, R plasmids, and integrons, associated to horizontal gene transfer usually found in gram-negative clinical isolates. Moreover, the similar GC% between the *trfA* replicon of the IncP plasmid and the *A. xylosoxidans* genome reinforces the argument that *A. xylosoxidans* could be considered as a reservoir of transferable elements. It is likely that its intrinsic antibiotic multidrug resistant profile that ensures its selection under antibiotic pressure, along with its ability to survive in fluids and in the environment \[[@CR18]\], makes *A. xylosoxidans* a reservoir of transferable elements that could contribute to the dissemination and acquisition of antimicrobial resistance mechanisms within the nosocomial environment.
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